MX336091B - Anticuerpos contra el extodominio de erbb3 y usos de los mismos. - Google Patents
Anticuerpos contra el extodominio de erbb3 y usos de los mismos.Info
- Publication number
- MX336091B MX336091B MX2012002172A MX2012002172A MX336091B MX 336091 B MX336091 B MX 336091B MX 2012002172 A MX2012002172 A MX 2012002172A MX 2012002172 A MX2012002172 A MX 2012002172A MX 336091 B MX336091 B MX 336091B
- Authority
- MX
- Mexico
- Prior art keywords
- erbb3
- antibodies
- receptor
- antigen binding
- binding fragments
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 102000056372 ErbB-3 Receptor Human genes 0.000 abstract 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23579909P | 2009-08-21 | 2009-08-21 | |
| PCT/US2010/046364 WO2011022727A2 (en) | 2009-08-21 | 2010-08-23 | Antibodies against the ectodomain of erbb3 and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012002172A MX2012002172A (es) | 2012-05-29 |
| MX336091B true MX336091B (es) | 2016-01-08 |
Family
ID=43607614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002172A MX336091B (es) | 2009-08-21 | 2010-08-23 | Anticuerpos contra el extodominio de erbb3 y usos de los mismos. |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP2467164A2 (de) |
| JP (1) | JP5752687B2 (de) |
| KR (1) | KR20120059568A (de) |
| CN (1) | CN103002912A (de) |
| AU (1) | AU2010284018C1 (de) |
| BR (1) | BR112012003809A2 (de) |
| CA (1) | CA2771744A1 (de) |
| CR (1) | CR20120108A (de) |
| DO (1) | DOP2012000044A (de) |
| EA (1) | EA201200195A1 (de) |
| EC (1) | ECSP12011740A (de) |
| IL (1) | IL218097A0 (de) |
| IN (1) | IN2012DN01518A (de) |
| MA (1) | MA33582B1 (de) |
| MX (1) | MX336091B (de) |
| NI (1) | NI201200027A (de) |
| PE (1) | PE20121585A1 (de) |
| SG (1) | SG178509A1 (de) |
| TN (1) | TN2012000057A1 (de) |
| WO (1) | WO2011022727A2 (de) |
| ZA (1) | ZA201201195B (de) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ579644A (en) | 2007-02-16 | 2012-05-25 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| TWI630916B (zh) | 2009-11-13 | 2018-08-01 | 第一三共歐洲公司 | 供治療或預防人表皮生長因子受體－３（ｈｅｒ－３）相關疾病之藥料和方法 |
| NZ600262A (en) | 2009-12-22 | 2013-06-28 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
| SG183532A1 (en) | 2010-03-11 | 2012-09-27 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| ES2566602T3 (es) | 2010-04-09 | 2016-04-14 | Aveo Pharmaceuticals, Inc. | Anticuerpos anti-ErbB3 |
| CN105037552B (zh) | 2010-08-20 | 2019-03-29 | 诺华股份有限公司 | 表皮生长因子受体3（her3)的抗体 |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| IT1402149B1 (it) * | 2010-10-04 | 2013-08-28 | Ist Fisioterap Ospitalroma | Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2. |
| KR101773120B1 (ko) | 2010-11-01 | 2017-08-30 | 심포젠 에이/에스 | 항―ｈｅｒ3 항체 및 조성물 |
| CA2833643A1 (en) | 2011-04-19 | 2012-10-26 | Merrimack Pharmaceuticals, Inc. | Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies |
| EP2722343A4 (de) * | 2011-06-20 | 2014-12-17 | Kyowa Hakko Kirin Co Ltd | Anti-erbb3-antikörper |
| AU2012316402B2 (en) | 2011-09-30 | 2017-04-20 | Regeneron Pharmaceuticals, Inc. | Anti-ErbB3 antibodies and uses thereof |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| CN108753942A (zh) | 2011-10-06 | 2018-11-06 | Aveo制药公司 | 预测肿瘤对抗erbb3抗体的应答 |
| CA2855298A1 (en) * | 2011-11-09 | 2013-05-16 | The Uab Research Foundation | Her3 antibodies and uses thereof |
| KR102218497B1 (ko) | 2011-12-05 | 2021-02-22 | 노파르티스 아게 | 표피 성장 인자 수용체 3 (her3)에 대한 항체 |
| WO2013124297A1 (en) * | 2012-02-22 | 2013-08-29 | U3 Pharma Gmbh | Combination of hb-egf binding protein and egfr inhibitor |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| WO2015058108A1 (en) * | 2013-10-17 | 2015-04-23 | Sanford-Burnham Medical Research Institute | Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| AU2015223566B2 (en) * | 2014-02-28 | 2020-10-08 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
| CN105367657B (zh) * | 2014-08-14 | 2019-09-13 | 上海生物制品研究所有限责任公司 | 抗her3抗体、其制法及其应用 |
| WO2016038609A1 (en) * | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| JP2017534574A (ja) | 2014-09-08 | 2017-11-24 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． | チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| DK3365373T3 (da) | 2015-10-23 | 2021-04-06 | Merus Nv | Bindingsmolekyler, der hæmmer cancervækst |
| MX2019011660A (es) | 2017-03-31 | 2019-11-18 | Merus Nv | Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1). |
| MX2019013804A (es) | 2017-05-17 | 2020-02-24 | Merus Nv | Combinacion de un anticuerpo biespecifico de erbb-2/erbb-3 con terapia endocrina para cancer de mama. |
| WO2019028555A1 (en) | 2017-08-09 | 2019-02-14 | University Of Saskatchewan | HER3 BINDING AGENTS AND USES THEREOF |
| HRP20250474T2 (hr) | 2017-08-09 | 2025-08-01 | Merus N.V. | Antitijela koja se vežu za egfr i cmet |
| GB201804094D0 (en) * | 2018-03-14 | 2018-04-25 | Ultrahuman Thirteen Ltd | ERBB3 Binding agents |
| US20210246223A1 (en) * | 2018-06-22 | 2021-08-12 | Crd Pharmaceuticals Inc | ANTI-HER3 Antibody and uses thereof |
| CN116133694A (zh) * | 2020-10-14 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | 抗her3抗体和抗her3抗体药物偶联物及其医药用途 |
| MX2023005940A (es) * | 2020-11-20 | 2023-07-27 | Actinium Pharmaceuticals Inc | Radioinmunoterapia con her3 para el tratamiento de canceres solidos. |
| CN117500832A (zh) * | 2021-06-15 | 2024-02-02 | 北京先通生物医药技术有限公司 | 抗her3抗体、含有该抗体的抗体药物缀合物及其用途 |
| CN119013307A (zh) * | 2022-04-13 | 2024-11-22 | 上海翰森生物医药科技有限公司 | 抗体或其抗原结合片段及其医药用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ579644A (en) * | 2007-02-16 | 2012-05-25 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
-
2010
- 2010-08-23 PE PE2012000234A patent/PE20121585A1/es not_active Application Discontinuation
- 2010-08-23 BR BR112012003809A patent/BR112012003809A2/pt not_active IP Right Cessation
- 2010-08-23 KR KR1020127007280A patent/KR20120059568A/ko not_active Withdrawn
- 2010-08-23 EP EP10810721A patent/EP2467164A2/de not_active Withdrawn
- 2010-08-23 SG SG2012011664A patent/SG178509A1/en unknown
- 2010-08-23 MX MX2012002172A patent/MX336091B/es unknown
- 2010-08-23 JP JP2012525756A patent/JP5752687B2/ja not_active Ceased
- 2010-08-23 AU AU2010284018A patent/AU2010284018C1/en not_active Ceased
- 2010-08-23 IN IN1518DEN2012 patent/IN2012DN01518A/en unknown
- 2010-08-23 EA EA201200195A patent/EA201200195A1/ru unknown
- 2010-08-23 CA CA2771744A patent/CA2771744A1/en not_active Abandoned
- 2010-08-23 WO PCT/US2010/046364 patent/WO2011022727A2/en not_active Ceased
- 2010-08-23 CN CN2010800477186A patent/CN103002912A/zh active Pending
-
2012
- 2012-02-09 TN TNP2012000057A patent/TN2012000057A1/en unknown
- 2012-02-14 IL IL218097A patent/IL218097A0/en unknown
- 2012-02-15 NI NI201200027A patent/NI201200027A/es unknown
- 2012-02-17 ZA ZA2012/01195A patent/ZA201201195B/en unknown
- 2012-02-20 DO DO2012000044A patent/DOP2012000044A/es unknown
- 2012-03-05 CR CR20120108A patent/CR20120108A/es unknown
- 2012-03-12 MA MA34684A patent/MA33582B1/fr unknown
- 2012-03-21 EC ECSP12011740 patent/ECSP12011740A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2467164A2 (de) | 2012-06-27 |
| PE20121585A1 (es) | 2012-11-29 |
| CR20120108A (es) | 2012-06-05 |
| CN103002912A (zh) | 2013-03-27 |
| JP5752687B2 (ja) | 2015-07-22 |
| ECSP12011740A (es) | 2013-02-28 |
| WO2011022727A3 (en) | 2013-06-27 |
| NI201200027A (es) | 2013-01-29 |
| ZA201201195B (en) | 2015-07-29 |
| MX2012002172A (es) | 2012-05-29 |
| JP2013506622A (ja) | 2013-02-28 |
| IN2012DN01518A (de) | 2015-06-05 |
| MA33582B1 (fr) | 2012-09-01 |
| WO2011022727A2 (en) | 2011-02-24 |
| AU2010284018A1 (en) | 2012-03-22 |
| EA201200195A1 (ru) | 2012-12-28 |
| KR20120059568A (ko) | 2012-06-08 |
| DOP2012000044A (es) | 2012-06-30 |
| AU2010284018B2 (en) | 2014-06-05 |
| TN2012000057A1 (en) | 2013-09-19 |
| AU2010284018C1 (en) | 2015-10-15 |
| SG178509A1 (en) | 2012-04-27 |
| IL218097A0 (en) | 2012-04-30 |
| CA2771744A1 (en) | 2011-02-24 |
| BR112012003809A2 (pt) | 2019-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2012000057A1 (en) | Antibodies against the ectodomain of erbb3 and uses thereof | |
| MX2009008656A (es) | Anticuerpos contra erbb3 y usos de los mismos. | |
| PH12019501115A1 (en) | Anti-cd134 (ox40) antibodies and uses thereof | |
| PH12015501243A1 (en) | Compositions and methods for antibodies targeting epo | |
| PH12015500390B1 (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
| MX2014014951A (es) | Agentes aglutinantes que modulan la trayectoria hippo y sus usos. | |
| CY1122978T1 (el) | Αντισωματα εναντι-vla-4 | |
| MX366223B (es) | Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2. | |
| PH12012501157A1 (en) | Anti-her3 antibodies and uses thereof | |
| MX347515B (es) | Agentes que se unen al receptor encrespado y usos de los mismos. | |
| WO2012058592A3 (en) | Non-antagonistic egfr-binding molecules and immunoconjugates thereof | |
| MX375439B (es) | Moleculas de union cd37 y sus inmunoconjugados. | |
| AU2011338480A8 (en) | Humanized antibodies to LIV-1 and use of same to treat cancer | |
| TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
| NZ712903A (en) | Humanized anti-cd134 (ox40) antibodies and uses thereof | |
| IN2014CN04373A (de) | ||
| PH12015500752A1 (en) | Her3 antigen binding proteins binding to the beta-hairpin of her3 | |
| IN2014DN09717A (de) | ||
| PH12015500751A1 (en) | Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4 | |
| IN2014CN04374A (de) | ||
| WO2015048008A3 (en) | Binding molecules specific for her3 and uses thereof | |
| PH12019500677A1 (en) | Cmet monoclonal binding agents, drug conjugates thereof and uses thereof | |
| HK1166273A (en) | Antibodies against the ectodomain of erbb3 and uses thereof | |
| MX2015004892A (es) | Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21. |